OEM Carrier Furnace HC660007 317292-752 317292-751 Motor Inducer Payne Bryant HVAC Parts & Accessories


  1. Home
  2. OEM Carrier Furnace HC660007 317292-752 317292-751 Motor Inducer Payne Bryant
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
OEM Carrier Bryant Payne Inducer Motor 317292-751 317292-752 HC660007 Furnace
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

Carrier Bryant ne

MPN:

1628

UPC:

Does Not Apply

published on tue nov 09 2021

OEM Carrier Furnace HC660007 317292-752 317292-751 Motor Inducer Payne Bryant HVAC Parts & Accessories

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

OEM Carrier Furnace HC660007 317292-752 317292-751 Motor Inducer Payne Bryant HVAC Parts & Accessories

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS